Total Payments
$8,439
2024 Payments
$1,415
Companies
30
Transactions
217
Medicare Patients
2,342
Medicare Billing
$314,335
Payment Breakdown by Category
Food & Beverage$4,905 (58.1%)
Other$2,503 (29.7%)
Consulting$885.00 (10.5%)
Education$146.60 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,905 | 206 | 58.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,503 | 3 | 29.7% |
| Consulting Fee | $885.00 | 2 | 10.5% |
| Education | $146.60 | 6 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $3,556 | 7 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $735.19 | 37 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $601.04 | 25 | $0 (2024) |
| Merck Sharp & Dohme LLC | $497.16 | 11 | $0 (2024) |
| Genentech USA, Inc. | $378.92 | 23 | $0 (2020) |
| Eisai Inc. | $314.55 | 13 | $0 (2024) |
| Amgen Inc. | $284.12 | 15 | $0 (2021) |
| Stemline Therapeutics Inc. | $237.30 | 8 | $0 (2024) |
| PFIZER INC. | $227.54 | 5 | $0 (2024) |
| Lilly USA, LLC | $199.74 | 12 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,415 | 44 | AstraZeneca Pharmaceuticals LP ($346.09) |
| 2023 | $558.08 | 21 | Stemline Therapeutics Inc. ($145.28) |
| 2022 | $168.70 | 7 | E.R. Squibb & Sons, L.L.C. ($50.23) |
| 2021 | $84.89 | 5 | E.R. Squibb & Sons, L.L.C. ($33.83) |
| 2020 | $308.10 | 14 | Astellas Pharma US Inc ($64.99) |
| 2019 | $3,429 | 48 | Celgene Corporation ($2,643) |
| 2018 | $867.36 | 41 | E.R. Squibb & Sons, L.L.C. ($238.32) |
| 2017 | $1,608 | 37 | Celgene Corporation ($885.00) |
All Payment Transactions
217 individual payment records from CMS Open Payments — Page 9 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/12/2017 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: Hematology | ||||||
| 05/23/2017 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: BioOncology | ||||||
| 05/22/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.96 | General |
| Category: Oncology | ||||||
| 05/10/2017 | Otsuka America Pharmaceutical, Inc. | SPRYCEL (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: HEMATOLOGY | ||||||
| 04/20/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Education | Cash or cash equivalent | $6.25 | General |
| Category: Cardiovascular | ||||||
| 04/11/2017 | Amgen Inc. | Neulasta (Biological) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: Oncology | ||||||
| 04/10/2017 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: BioOncology | ||||||
| 03/29/2017 | Celgene Corporation | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Hematology / Oncology | ||||||
| 03/28/2017 | Genentech USA, Inc. | Perjeta (Biological), Kadcyla | Food and Beverage | In-kind items and services | $12.19 | General |
| Category: BioOncology | ||||||
| 03/21/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Oncology | ||||||
| 03/15/2017 | Genentech USA, Inc. | Perjeta (Biological), Kadcyla | Food and Beverage | In-kind items and services | $10.42 | General |
| Category: BioOncology | ||||||
| 03/13/2017 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Hematology | ||||||
| 02/15/2017 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: BioOncology | ||||||
| 02/14/2017 | Genentech USA, Inc. | Herceptin (Biological), Perjeta | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: BioOncology | ||||||
| 01/23/2017 | Otsuka America Pharmaceutical, Inc. | SPRYCEL (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: HEMATOLOGY | ||||||
| 01/11/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.78 | General |
| Category: Oncology | ||||||
| 01/09/2017 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 497 | 665 | $236,666 | $68,501 |
| 2022 | 7 | 571 | 951 | $250,352 | $81,811 |
| 2021 | 8 | 669 | 1,102 | $264,849 | $95,019 |
| 2020 | 10 | 605 | 1,040 | $238,742 | $69,004 |
Total Patients
2,342
Total Services
3,758
Medicare Billing
$314,335
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 228 | 345 | $110,702 | $32,607 | 29.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 100 | 133 | $59,005 | $17,738 | 30.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 52 | 52 | $30,089 | $7,899 | 26.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 32 | $6,800 | $2,195 | 32.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $8,430 | $2,090 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 22 | 23 | $5,750 | $1,554 | 27.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $5,962 | $1,413 | 23.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 14 | $4,046 | $1,338 | 33.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 12 | 12 | $3,827 | $1,178 | 30.8% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 11 | 26 | $2,054 | $490.13 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 309 | 606 | $142,280 | $45,762 | 32.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 90 | 154 | $49,352 | $17,756 | 36.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 58 | 58 | $26,414 | $8,223 | 31.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 16 | $6,416 | $2,374 | 37.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 48 | 52 | $7,970 | $2,325 | 29.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $6,876 | $2,176 | 31.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 26 | $4,980 | $1,532 | 30.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $4,754 | $1,384 | 29.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 12 | 14 | $1,310 | $278.80 | 21.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 322 | 648 | $149,040 | $52,053 | 34.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 108 | 167 | $51,937 | $21,028 | 40.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 58 | 58 | $25,868 | $9,005 | 34.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 75 | 87 | $13,311 | $5,041 | 37.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 32 | 63 | $11,718 | $3,794 | 32.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 18 | 18 | $6,282 | $2,064 | 32.8% |
About Dr. Kala Seetharaman, MD
Dr. Kala Seetharaman, MD is a Hematology & Oncology healthcare provider based in Worcester, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1710969050.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kala Seetharaman, MD has received a total of $8,439 in payments from pharmaceutical and medical device companies, with $1,415 received in 2024. These payments were reported across 217 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($4,905).
As a Medicare-enrolled provider, Seetharaman has provided services to 2,342 Medicare beneficiaries, totaling 3,758 services with total Medicare billing of $314,335. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Worcester, MA
- Active Since 11/14/2005
- Last Updated 09/24/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1710969050
Products in Payments
- Revlimid (Drug) $3,528
- OPDIVO (Biological) $508.43
- KEYTRUDA (Biological) $497.16
- Lenvima (Drug) $295.87
- SPRYCEL (Drug) $247.05
- Orserdu (Drug) $237.30
- BOSULIF (Drug) $173.82
- ENHERTU (Biological) $164.95
- Cabometyx (Drug) $158.50
- LYNPARZA (Drug) $153.31
- Perjeta (Biological) $144.76
- Imbruvica (Drug) $106.83
- PADCEV (Biological) $106.66
- Nplate (Biological) $103.39
- IMFINZI (Biological) $95.63
- CYRAMZA (Drug) $84.92
- Stivarga (Drug) $83.03
- TAGRISSO (Drug) $81.82
- BRUKINSA (Drug) $79.35
- Avastin (Biological) $68.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Worcester
Dr. Tariq Mughal, M.d, M.D
Hematology & Oncology — Payments: $342,612
Hematology & Oncology $342,612
Viola Zhu, Md Phd, MD PHD
Hematology & Oncology — Payments: $270,026
Hematology & Oncology $270,026
James Rooney, M.d, M.D
Hematology & Oncology — Payments: $20,015
Hematology & Oncology $20,015
Dr. Shyam Patel, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $14,978
Hematology & Oncology $14,978
Madhavi Toke, Md, MD
Hematology & Oncology — Payments: $9,823
Hematology & Oncology $9,823
Vijay Kasturi, M.d, M.D
Hematology & Oncology — Payments: $9,810
Hematology & Oncology $9,810